Key points are not available for this paper at this time.
Background: The 2019 ESC/EASD recommendations classified cardiovascular risk (CV) in diabetes mellitus (DM). The CV risk assessment and stratification were essential for identifying persons with a very high risk of CVD and active targeted interventions. The purpose of this research is to fill in the lack of epidemiological data on the classification of individuals with a very high cardiovascular risk in patients with type 1 diabetes mellitus (T1DM) from different regions across China. Methods: This multicenter, cross-sectional, non-interventional study gathered information such as disease duration, body mass index (BMI), traget organ damage including atherosclerotic heart disease, impaired renal function, left ventricular hypertrophy and retinopathy, from outclinic patients by trained doctors. We use the 2019 ESC/EASD standards divided T1DM patients into two categories: with a very high risk and else. Results: A total of 38260 participants from more than 2,000 hospitals in 30 provinces of China were enrolled from 2020 to 2022, of which 54.81% of T1DM were at very high CV risk. The proportions of very high-risk T1DM were higher in Northeast (72.70%), Southwest (69.99%) and Central (54.41%), while the lowest was Southern China (47.03%). The proportion of very high risk of CV risk in T1DM increased with age and BMI, 33.61% in those among 35 years old subgroups, while in 35-65 years old were 59.57% and among 65 years old was 70.80%. (P 0.0001). Male and smoker showed increased prevalence of the very high CV risk in T1DM (P 0.0001). Conclusion: This study is the largest observational study of CV risk assessment in T1DM patients in China. The CV risk situation of diabetic patients in China is critical, and comprehensive control and management of CV-related risk factors such as blood pressure, BMI, and lipids in DM patients need to be strengthened so as to reduce the risk of cardiovascular events and death. Disclosure W. Wang: None. L. Guo: Consultant; Abbott, AstraZeneca, Bayer Inc., Boehringer-Ingelheim, Eli Lilly and Company, Hengrui (USA) Ltd., Dreisamtech, Dongbao, Gan & Lee, Hansoh. Q. Pan: None. Funding This study was supported by Beijing Great Physician Commonwealth Foundation "CV Risk Evaluation" program
Wang et al. (Fri,) studied this question.